Scienture Holdings, Inc. (SCNX)
NASDAQ: SCNX · Real-Time Price · USD
0.3950
+0.0050 (1.28%)
At close: Apr 17, 2026, 4:00 PM EDT
0.3900
-0.0050 (-1.27%)
After-hours: Apr 17, 2026, 7:35 PM EDT
Scienture Holdings Revenue
In the year 2025, Scienture Holdings had annual revenue of $431.61K with 215.87% growth. Scienture Holdings had revenue of $-168.70K in the quarter ending December 31, 2025.
Revenue (ttm)
$431.61K
Revenue Growth
+215.87%
P/S Ratio
37.18
Revenue / Employee
$47,957
Employees
9
Market Cap
16.05M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 431.61K | 294.97K | 215.87% |
| Dec 31, 2024 | 136.64K | -1.23M | -89.98% |
| Dec 31, 2023 | 1.36M | -8.89M | -86.69% |
| Dec 31, 2022 | 10.25M | 360.77K | 3.65% |
| Dec 31, 2021 | 9.89M | -7.23M | -42.24% |
| Dec 31, 2020 | 17.12M | 9.69M | 130.26% |
| Dec 31, 2019 | 7.44M | 3.60M | 94.07% |
| Dec 31, 2018 | 3.83M | 900.50K | 30.72% |
| Dec 31, 2017 | 2.93M | 449.41K | 18.11% |
| Dec 31, 2016 | 2.48M | -430.66K | -14.79% |
| Dec 31, 2015 | 2.91M | 1.42M | 94.66% |
| Dec 31, 2014 | 1.50M | 540.35K | 56.53% |
| Dec 31, 2013 | 955.88K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 96.36B |
| Eli Lilly and Company | 65.18B |
| AbbVie | 61.16B |
| AstraZeneca | 58.74B |
| Jin Medical International | 20.69M |
| Traws Pharma | 2.79M |
| SeaStar Medical Holding | 1.23M |
| Vyome Holdings | 319.71K |
SCNX News
- 19 days ago - SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions - GlobeNewsWire
- 2 months ago - SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium - GlobeNewsWire
- 3 months ago - SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment - GlobeNewsWire
- 4 months ago - SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA - GlobeNewsWire
- 4 months ago - SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium - GlobeNewsWire
- 4 months ago - SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025 - GlobeNewsWire
- 5 months ago - SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update - GlobeNewsWire